Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01924221 · ClinicalTrials.gov registry record

Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy

A clinical trial of Heart Failure and Patients Undergoing CRT-D Device Implantation, sponsored by Johns Hopkins University.

Completed
Registry status
31
Enrollment target
1
Study location

NCT01924221: Completed study of Heart Failure and Patients Undergoing CRT-D Device Implantation, sponsored by Johns Hopkins University.

NCT01924221 is a study of Heart Failure and Patients Undergoing CRT-D Device Implantation that has completed, run by Johns Hopkins University. The registered enrollment target is 31 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01924221, a study of Heart Failure and Patients Undergoing CRT-D Device Implantation, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
31 participants
Enrollment target
1
Study location

Study Summary

Cardiac resynchronization therapy with pacemaker alone, or in combination with a cardioverter-defibrillator, prolongs life and decreases risk of heart failure exacerbation in patients with low ejection fraction and wide QRS. Some patients achieve decrease in QRS duration 6 months after cardiac resynchronization therapy. Such phenomenon is called reverse electrical remodeling of native conduction. Retrospective analysis showed that reverse electrical remodeling of the native conduction after at least 6 months of CRT is associated with decreased rate of ventricular arrhythmias and better survival. This study is designed to study reverse electrical remodeling prospectively.

Primary Outcome

correlation between electrical and mechanical measures of dyssynchrony

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2011-12
Est. Completion 2022-08-01
Johns Hopkins University

1,448 total trials

What the finished NCT01924221 record still lists

NCT01924221 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.

NCT01924221 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01924221 about?

NCT01924221 is a clinical study titled "Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy". Cardiac resynchronization therapy with pacemaker alone, or in combination with a cardioverter-defibrillator, prolongs life and decreases risk of heart failure exacerbation in patients with low ejection fraction and wide QRS. Some patients achieve decrease in QRS duration 6 months after cardiac resyn...

What is the current status of trial NCT01924221?

This trial is currently completed. The enrollment target is 31 participants. The study started on 2011-12. Estimated completion is 2022-08-01.

What conditions does trial NCT01924221 study?

This clinical trial studies the following conditions: Heart Failure, Patients Undergoing CRT-D Device Implantation.

Who is sponsoring clinical trial NCT01924221?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01924221 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01924221's enrollment target sits among peer trials

31 319th of 397 higher than 77 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02932618 · 31 participants · Phase 3

    A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

  • NCT03482297 · 31 participants · Phase 1

    Automated Abdominal Binder for Orthostatic Hypotension

  • NCT04016389 · 31 participants · NA

    FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

  • NCT04211675 · 31 participants · Phase 1

    NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01924221, the US trial registry maintained by the National Library of Medicine. NCT01924221 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.